Serevent Powder, Metered
Product Images NDC 0173-0521

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Serevent (NDC 0173-0521). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glaxosmithkline Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Salmeterol Chemical Structure (Sereventdiskus Spl Graphic 01)

Chemical structure diagram of salmeterol xinafoate, the active ingredient in SEREVENT DISKUS. The diagram shows two main chemical structures representing the salmeterol molecule and the xinafoate moiety.*

FDA Label Image

Figure 1 First Treatment Day (Sereventdiskus Spl Graphic 02)

A line graph comparing the percentage of predicted FEV1 over 12 hours after dosing for three groups: SEREVENT DISKUS 50 mcg twice daily, Albuterol inhalation aerosol 180 mcg four times daily, and placebo. The graph shows changes in lung function across time post-dose for each treatment group.*

FDA Label Image

Figure 1 Week 12 (Sereventdiskus Spl Graphic 03)

A line graph comparing FEV1 (% of predose) over 12 hours for three groups: SEREVENT DISKUS 50 mcg twice daily, Albuterol inhalation aerosol 180 mcg 4 times daily, and placebo. The x-axis represents time in hours and the y-axis shows FEV1 percentage change from predose.*

FDA Label Image

Figure 2. Cumulative Incidence Of Asthma-related Deaths In The 28-week Salmeterol Multi-center Asthma Research Trial (smart), By Duration Of Treatment (Sereventdiskus Spl Graphic 04)

Three line graphs depict asthma-related death cumulative incidence over treatment duration in days for SEREVENT DISKUS (salmeterol xinafoate) versus placebo. The first graph shows data for all subjects, the second for Caucasians, and the third for African Americans. Below each graph are corresponding tables listing the number of subjects at risk at the start of each interval for both groups.*

FDA Label Image

Figure 3. Mean Percent Change From Baseline In Postdose Fev1 Integrated Data From 2 Trials Of Subjects With Chronic Bronchitis And Airflow Limitation (Sereventdiskus Spl Graphic 05)

A bar chart comparing the percentage change in FEV1 (forced expiratory volume) over time between SEREVENT DISKUS 50 mcg twice daily and placebo groups. Data points are shown at Day 1, Week 12, Week 24, and study endpoint, with sample sizes indicated for each group. The chart illustrates higher improvements in FEV1 for the SEREVENT DISKUS group compared to placebo across all time points.*

FDA Label Image

Figure 4. Serial 12-hour Fev1 On The First Day And At Week 12 Of Treatment (Sereventdiskus Spl Graphic 06)

Line chart showing change from baseline FEV1 (L/sec) over 12 hours on Days 1 and 12 comparing SEREVENT DISKUS 50 mcg twice daily to placebo. The graph displays FEV1 values on the y-axis and time in hours on the x-axis, illustrating greater improvement for SEREVENT DISKUS than placebo at both time points.*

FDA Label Image

Figure A (Sereventdiskus Spl Graphic 07)

Illustration of the SEREVENT DISKUS inhaler showing labeled parts including the outer case, mouthpiece, lever, thumb grip, and counter. The label indicates 60 blisters of salmeterol xinafoate inhalation powder at 50 mcg strength, designed for oral respiratory inhalation.*

FDA Label Image

Figure B (Sereventdiskus Spl Graphic 08)

Illustration showing a person holding a SEREVENT DISKUS inhaler with their fingers pressing on the sides to open it, indicated by a right-pointing arrow.*

FDA Label Image

Figure C (Sereventdiskus Spl Graphic 09)

An instructional illustration showing how to hold and operate the SEREVENT DISKUS inhaler. The image depicts two hands gripping the green SEREVENT DISKUS device, with an arrow indicating the motion to open or slide the inhaler for use.*

FDA Label Image

Figure D (Sereventdiskus Spl Graphic 10)

An illustration showing a woman holding a green SEREVENT DISKUS inhaler device near her mouth, demonstrating the proper use of this respiratory powder metered-dose inhalation product containing salmeterol xinafoate.*

FDA Label Image

Figure E (Sereventdiskus Spl Graphic 11)

An image showing a woman using a green inhaler device, demonstrating the proper method of inhalation for a powdered respiratory medication. The illustration highlights patient use technique for inhalation therapy.*

FDA Label Image

Figure F (Sereventdiskus Spl Graphic 12)

Illustration showing hands holding the SEREVENT DISKUS inhaler, demonstrating the action of sliding the device to prepare a dose for inhalation. The diagram uses an arrow to indicate the sliding direction, consistent with the use of a powder inhaler for respiratory delivery.*

FDA Label Image

Figure G (Sereventdiskus Spl Graphic 13)

SEREVENT DISKUS 50 mcg powder, metered, respiratory inhalation device. This green, circular plastic inhaler displays the product name, strength, and form on a white label on the front with the labeler GlaxoSmithKline LLC noted. It contains 60 blisters of powder for oral inhalation.*

FDA Label Image

Serevent Diskus 50 Mcg 60 Dose Carton (Sereventdiskus Spl Graphic 14)

SEREVENT DISKUS 50 mcg metered powder for oral inhalation, containing salmeterol xinafoate. The label indicates the product includes 1 Diskus inhalation device with 1 foil strip of 60 blisters. Manufactured by GlaxoSmithKline LLC, the label emphasizes federal law requirements for dispensing with a medication guide and directs to prescribing information for dosing.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.